(1 - 20 from 33
)
NextCure to Present Clinical Data from NC318 Phase
ir.nextcure.com
Lead Author: Anthony Tolcher , MD, FRCPC, FACP, Director of Clinical Research, NEXT Oncology. About NC318 NC318 is a first-in-class immunomedicine against ... › news-release-details › nextcure...
Dr. Anthony Tolcher is revolutionizing clinical research in San...
article.wn.com
Mar 19, · Dr. Anthony Tolcher is revolutionizing clinical research in San Antonio and worldwide, enabling cutting-edge cancer care
Caltech-led Team Provides Proof in Humans of RNA Interference Using...
www.caltech.edu
A Caltech-led team of researchers and clinicians has published the first proof that a targeted nanoparticle—used as an experimental the…utic and...
START Researchers Continue to Usher In a New Era of Precision...
sanantonio.mdnews.com
Newly approved Keytruda has a well-known link to San Antonio, where START researchers first showed the drug can be an effective treatment for both lung cancer...
sorted by relevance / date